Case Series
Three preterm infants with severe BPD (36 weeks' postmenstrual age [PMA] ) were included (►Table 1) after Institutional Review Board (IRB) approval and waiver of informed consents. All infants had worsening respiratory status, increasing oxygen requirements, and significantly high NTproBNP levels (7,585 AE 7,079 ng/dL). All infants had ECHO evidence of PH (right ventricular hypertrophy, flattening of the interventricular septum, pulmonary artery pressure [PAP] > 30 mm Hg estimated by tricuspid jet velocity). 9 Other comorbidities (aspiration, gastroesophageal reflux disease, structural airway disease, pulmonary arterial/venous stenosis, cardiac dysfunction) were ruled out before making the presumptive diagnosis of BPD-PH. Sildenafil was started orally and the dose was gradually increased up to 8 mg/kg/day divided four times daily. Serial NTproBNP levels were measured at 2 and 4 weeks after starting sildenafil. Respiratory severity scores (RSSs) (Mean airway pressure Â Fraction of inspired oxygen [FiO 2 ]) were calculated to determine respiratory support since these infants lacked arterial lines for measuring oxygenation indices. There was a significant reduction in NTproBNP levels in all the infants (►Fig. 1). RSS decreased significantly (a drop of > 20%
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) in 1 out of the 3 infants (62% drop in Case 1 after 4 weeks of therapy), while the other 2 infants required an escalation in respiratory support (►Table 2). ECHO was repeated at 4 weeks after starting sildenafil and showed improvement in two out of the three cases, with significant improvement (> 20% drop in PAP) only in Case 1 (►Table 2). No significant adverse effects of sildenafil were noted.
Discussion
In our case series, we have shown that the use of NTproBNP in conjunction with ECHO was a good screening tool for BPD-PH. All infants had significantly high NTproBNP levels and ECHO changes of PH. The highest NTproBNP levels were seen in Case 1 and Case 2, likely associated with the small for gestational age status of these infants. Inhaled nitric oxide is not used by our group for the treatment of BPD-PH since the minimal benefits (7% reduction in composite outcome of death or BPD 11 ) do not outweigh the need for intubation and the high costs/resources involved. The use of sildenafil dropped NTproBNP levels significantly in all patients and two infants (Case 1 and 3) had improved ECHO changes of PH. However, improvement in Case 3 was < 20% and does not meet clinical significance as determined by other studies.
10 RSS improved significantly in one infant while the other two required increasing respiratory support.
Sildenafil in BPD-PH
Sildenafil is a PDE5 inhibitor that mediates vasodilation by increasing intracellular cGMP levels. It also minimizes pulmonary arterial vasoreactivity and may prevent structural Abbreviations: AGA, appropriate for gestational age; BW, birth weight; GA, gestational age; PDA, patent ductus arteriosus; RDS, respiratory distress syndrome; SGA, small for gestational age. 17 We speculate that the late initiation of pulmonary vasodilator therapy (after irreversible pulmonary vascular changes had set in) may play a role in the lack of improvement in respiratory status in some infants.
Screening for BPD-PH
A prospective cohort study on 60 very PIs demonstrated that elevated BNP (B-type natriuretic peptide) levels at 36 weeks' PMA were significantly associated with the severity of BPD.
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A retrospective study evaluated the role of BNP and ECHO in screening for BPD-PH. BNP levels were measured within 10 days of the ECHO. They found that the median BNP levels were significantly higher in infants with BPD-PH (p < 0.001) and further a BNP value of 117 pg/mL had 93.8% sensitivity and 100% specificity for detecting BPD-PH. 19 A recent study enrolled PIs (< 27 weeks' gestational age [GA] and/or with a birth weight of 750 g), who met the criteria for BPD at 36 weeks' PMA. A screening ECHO at 36 to 38 weeks' PMA and plasma NTproBNP levels were significantly elevated in the BPD-PH group and the authors concluded that NTproBNP levels > 1,000 pg/mL may be a cost-effective screening biochemical marker for BPD-PH in PI. 20 We have also demonstrated that NTproBNP levels correlate well with ECHO evidence of BPD-PH (unpublished data-submitted to Journal of Perinatology). We measured NTproBNP levels in PIs (< 30 weeks' GA and < 1,500 g birth weight) at 28, 32, and 36 weeks' PMA. ECHO was also performed within 12 hours of obtaining NTproBNP levels to look for evidence of PH. Preliminary results have shown that neonates with ECHO evidence of PH had significantly elevated levels of NTproBNP (! 2,300 pg/mL) at 28, 32, and 36 weeks' PMA (p < 0.05). In our case series, we also found NTproBNP levels and ECHO were useful tools to screen for BPD-PH. Impaired angiogenesis during alveolar development leading to decreased vascular surface area, pulmonary arterial remodeling, and increased PVR are the proposed pathophysiological mechanisms involved in BPD-PH. 21 Prolonged exposure to increased right ventricular pressure leads to myocardial remodeling and pulmonary arterial fibrotic changes that are usually irreversible. Those infants may also be exposed to prolonged mechanical ventilation for progressive lung disease. Since these changes may begin long before 36 weeks' PMA, infants in our case series might have already developed irreversible pulmonary changes. This would explain the lack of improvement in respiratory status with sildenafil treatment. A prospective cohort study showed that the ratio of endostatin (an antiangiogenic factor) to angiopoiten-1 (a pro-angiogenic factor) was significantly higher on day 1 (median, 31.8 vs. 11.3) and day 7 (median, 62.1 vs. 19) in the BPD-PH group versus the no BPD group. 22 An increased endostatin to angiopoiten-1 ratio may reflect impaired angiogenesis and may be used for early biochemical screening of BPD-PH. Genetic and epigenetic biomarkers are also being studied as possible biomarkers for early screening of BPD-PH.
23
Are We Screening Early Enough?
We speculate that the initiation of sildenafil at ! 36 weeks' PMA in our case series improved pulmonary arterial pressures and reduced stress on the right heart (indirectly reflected by the significant drop in NTproBNP levels). However, this did not translate into consistent clinical improvement, as seen in other studies mentioned above, 10,17 likely due to irreversible changes in the pulmonary vasculature. Earlier screening and treatment of BPD-PH may be helpful to prevent these irreversible changes and improve short-and long-term clinical outcomes. Further studies of the natural history, screening biomarkers, and impact of therapeutic interventions like PDE5 inhibitors in BPD-PH are required. Early screening for BPD-PH with biomarkers like serial NTproBNP along with ECHO may be helpful in the diagnosis and management before irreversible changes occur.
Conclusion
The use of sildenafil in infants with BPD-PH improved rightsided pressures inconsistently but led to a consistent decline in markers of cardiac stress. We speculate that the lack of improvement in respiratory status in some infants may be due to irreversible pulmonary changes secondary to delay in diagnosis and initiation of pulmonary vasodilator therapy. Developing an early screening protocol for BPD-PH in PIs with significant respiratory disease (escalation of support/ increased oxygen requirement) may allow early initiation of therapeutic intervention with better outcomes. Multicenter studies are required to identify infants that need to be screened, develop screening protocols, and to determine the best timing of therapeutic intervention.
